Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of mutant EGF receptors by gefitinib: targeting an Achilles' heel of lung cancer.

Cell cycle (Georgetown, Tex.) - 1 Dec 2004

Settleman Jeffrey

Abstract excerpt

Recent reports revealed a strong correlation between the presence of somatic activating mutations in the kinase domain of the EGF receptor in some human lung cancers and a striking clinical response to the selective EGF receptor inhibitor, Gefitinib. These oncogenic receptors exhibit altered signaling properties such that they selectively activate downstream survival pathways on which tumor cells have become...

Topics

ErbB Receptors
Gefitinib
Humans
Lung Neoplasms
Mutation
Quinazolines

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 15539955
DOI: 10.4161/cc.3.12.1325

Genes

EGF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 29 Aug 2026. Prepared record publication-15539955-2026-08-29.1. Manifest publication-graph-cohort-2026-08-29.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 29 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of mutant EGF receptors by gefitinib: targeting an Achilles' heel of lung cancer.PMID 15539955Read ↗

EGFR kinase domain mutations - functional impact and relevance for lung cancer therapy.Semantic proximity Read ↗

Somatic mutations of the EGF receptor and their signal transducers affect the efficacy of EGF receptor-specific tyrosine kinase inhibitors.Semantic proximity Read ↗

EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer.Semantic proximity Read ↗

Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer.Semantic proximity Read ↗

Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants.Semantic proximity Read ↗

Biological and clinical implications of EGFR mutations in lung cancer.Semantic proximity Read ↗

Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants.Semantic proximity Read ↗

Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer.Semantic proximity Read ↗

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.Semantic proximity Read ↗

Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.Semantic proximity Read ↗

Predictive factors for epidermal growth factor receptor inhibitors--the bull's-eye hits the arrow.Semantic proximity Read ↗

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.